RE:RE:RE:RE:20 Million Ex Cash"Who knows where Siggy iS..."
She developed a marketing plan. A five year plan has been presented in presentations. Gilles said she would open doors for a CoQ10 deal. The CoQ10 data was announced last October and a plan had to be put together as CZO approached potential partners. Gilles has noted CZO is in talks with serious companies and that they understand bioavailability as a unique differentiator. Since Sigrun's arrival a preservative-free beta glucan powder has also been announced in development with Symrise. Detail the opportunities a powder form of beta glucan could open up. CZO also announced the scale-up of the avenanthramide malting technology opening up certain neutraceutical markets. A production run at small commercial scale has been achieved and now they are working on batch-to-batch consistency. What markets in neutraceuticals will be targeted? Gilles has said Sigrun would be working with Symrise to open doors. New opportunties can take time as products are tested, leading to a commercial decision, etc. CZO is also on record stating that it is looking at new revenue sources. These will each have to be investigated. CZO is before potentially the biggest corporate move to date as it also seeks to list on NASDAQ. A potential reverse-takeover could put a value on the pipeline opportunities CZO has developed, including with the help of Sigrun. A NASDAQ listed company could also have revenue sources that need investigation.